Human IL-15 Antibody - Ordesekimab Biosimilar
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hIL-15-hIgG1 Human IL-15 (Ordesekimab) antibody - Human IgG1 |
Show product |
100 µg 3 x 100 µg |
hil15-mab1
|
|
InvivoGen also offers:
Anti-human IL-15 - Ordesekimab biosimilar - CAS #879293-15-9
Anti-hIL-15-hIgG1 is a biosimilar antibody of Ordesekimab, a human interleukin-15 (IL-15) antibody that inhibits IL-15 signaling. This monoclonal antibody (mAb) is currently under investigation for the treatment of non-responsive celiac disease.
Anti-hIL-15-hIgG1 comprises the variable region of Ordesekimab and the IgG1 constant region of Ordesekimab.
This mAb can be used together with HEK-Blue™ IL-2/IL-15 cells for screening and neutralization assays to inhibit IL-15 signaling induced by recombinant human IL-15 (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined using the EndotoxDetect™ assay.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Figures
Specifications
Application: Neutralization assay, ELISA
Isotype: Human IgG1
Recommended isotype control: Human IgG1
Target: Human IL-15
Species reactivity: Human
Clone: Ordesekimab, AMG 714, PRV-015
Cas number: 879293-15-9
Sterility: 0.2 µm filtration
Source: CHO cells
Production: Animal-free
Purification: Protein A
Molecular weight: 145.1 kDa
Physical form: Lyophilized
Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Preservative: Azide-free
Reconstitution buffer: Sterile water (not provided)
Purity: ≥ 95 %
Quality control: Each lot is functionally tested and validated
Back to the topContents
Anti-hIL-15-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hil15-mab1: 100 µg
- hil15-mab1-03: 3 x 100 µg
The product is shipped at room temperature.
Upon receipt, store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year.
Avoid repeated freeze-thaw cycles.
Details
Ordesekimab and IL-15 background
Ordesekimab (also known as AMG 714 or PRV-015) is a fully human IgG1 monoclonal antibody (mAb) designed to target interleukin-15 (IL-15). By binding to IL-15, Ordesekimab inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not the interaction of IL-15 with the IL-15Rα chain [1].
IL-15 plays a vital role in supporting the function and survival of various cell types, and while its expression is normally well-controlled, elevated levels have been observed in several organ-specific autoimmune diseases [2]. In particular, it is described as a key driver of celiac disease, promoting the activation of intraepithelial CD8⁺ lymphocytes that destroy intestinal epithelial cells and lead to villous atrophy [3]. Given its central role in disease pathogenesis, IL-15 is an attractive therapeutic target.
The anti-hIL-15 mAb Ordesekimab is currently under clinical investigation for the treatment of non-responsive celiac disease, where patients continue to experience symptoms and intestinal damage despite adherence to a gluten-free diet [1].
References:
1. Wei YL, et al., 2022. Strategies to evaluate potential effector function of glycan variants: a case study of ordesekimab (AMG 714 or PRV-015). J Immunotoxicol. (1):109-116.
2. Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014 Jul;260(1):221-34.
3. Lähdeaho ML, et al., 2019. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol.4(12):948-959.